A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

COVID-19 (Coronavirus) Update

Vaccine Updates | COVID-19 Information | Visitor Guidelines

Protocol No

GOG-3028/C-750-01

Principal Investigator

Denise Uyar

Phase

Description

To assess whether AGEN23034 administered alone or combination with another drug AGEN1884 response well to women with recurrent/persistent metastatic cervical cancer

Participating Institutions

Froedtert Hospital

Status

SRC APPROVAL

ClinicalTrials.gov

go to website